SMARCA4 and neoplasm: In contrast, SDUS cases, characterized by the loss of SMARCA4, demonstrate an immune-high microenvironment, marked by substantial infiltration of tumor-infiltrating lymphocytes (TILs) and increased PD-L1 expression, indicating a potentially more immunogenic tumor that could be more responsive to immunotherapy [21].